Cannabinoids and Pain for the Plastic Surgeon
While preclinical and early human studies suggest that oral and topical CBD may offer safe, adjunctive pain relief with minimal side effects.
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy
While adjunctive transdermal cannabidiol (ZYN002) at doses of 195 mg or 390 mg daily did not demonstrate statistically significant superiority over.
Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
Low-dose oral synthetic cannabidiol (20-30 mg daily) failed to provide clinically meaningful pain relief or improve sleep and mood scores compared to.
Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial
Clinicians should be cautious when prescribing CBD-dominant cannabis products, as they may produce stronger adverse effects than expected.
Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ 9 ‐Tetrahydrocannabinol Without Improving Its Analgesic Properties
Clinicians should be aware that while CBD may increase the psychoactive effects of THC, it does not enhance its analgesic properties.
Cannabinoid therapeutics in orofacial pain management: a systematic review
While current systemic and oral cannabinoid formulations lack robust evidence for managing acute orofacial and post-operative dental pain.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality.
Administering 20 mg of isolated cannabinol (CBN) nightly can effectively reduce nighttime awakenings and overall sleep disturbance in patients with.
Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study
Consider recommending CBD-dominant cannabis for patients with anxiety symptoms, as it may provide greater relief compared to THC-dominant options.
A Preliminary Pharmacokinetic Comparison of Δ-9 Tetrahydrocannabinol and Cannabidiol Extract Versus Oromucosal Spray in Healthy Men and Women
Clinicians should consider the route of administration when prescribing THC:CBD formulations, as bioavailability may vary significantly between methods.
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model
In this double-blind laboratory study, low-dose oral cannabidiol (50 mg) enhanced the acute analgesic properties of 4 mg hydromorphone without increasing.
